免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
这些发现突出表明,CTX 与 ICB 的联合是治疗免疫治疗难治性肿瘤的一种具有临床意义的方法。
英文原题:Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
TIL(肿瘤浸润淋巴细胞)过继细胞治疗可在转移性黑色素瘤中诱导持久缓解,然而在体外扩增过程中及回输后,调控肿瘤反应性T细胞命运的克隆和转录动态仍知之甚少。
TIL(肿瘤浸润淋巴细胞)过继细胞治疗可在转移性黑色素瘤中诱导持久缓解,但调控肿瘤反应性T细胞命运在体外扩增期间及回输后的克隆和转录动态仍知之甚少。在此,我们对7例黑色素瘤患者的五个时间点进行了纵向单细胞RNA和T细胞受体测序,涵盖基线肿瘤、两阶段体外扩增以及输注后血液和肿瘤活检,并解析了CD8+和CD4+两个区室。肿瘤反应性CD8+ T细胞从耗竭状态中被重新激活,并获得HLA-II高表达或KLF2高表达谱。我们进一步深入剖析了肿瘤反应性CD4+区室,揭示了谱系依赖性的重新激活,其中滤泡辅助T细胞采用效应状态,而耗竭的CD4+ T细胞则保留功能障碍。在三个队列的无应答者中,共转移的17型T细胞以及转移后新出现的调节性T细胞扩增与治疗失败相关。这些数据定义了跨越两个谱系的亚型特异性特征,以指导TIL扩增。
Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) induces durable responses in metastatic melanoma, yet the clonal and transcriptional dynamics governing tumor-reactive T cell fate during ex vivo expansion and after transfer remain poorly understood. Here, we perform longitudinal single-cell RNA and T cell receptor sequencing across five time points, from baseline tumors through two-phase ex vivo expansion to post-infusion blood and tumor biopsies, in seven melanoma patients, resolving both the CD8 + and CD4 + compartments. Tumor-reactive CD8 + T cells are reinvigorated from exhaustion and acquire HLA-II-high or KLF2-high profiles. We further dissect the tumor-responsive CD4 + compartment in depth, revealing lineage-dependent reinvigoration in which follicular helper T cells adopt an effector state while exhausted CD4 + T cells retain dysfunction. In non-responders, across three cohorts, co-transferred type 17 T cells and de novo regulatory T cell expansion after transfer associate with treatment failure. These data define subtype-specific signatures across both lineages to guide TIL expansion.
MEMBER ACCOUNT
登录成功会直接打开下一页。